Use of gelatinized maca (lepidium peruvianum) in early postmenopausal women

H O Meissner, W Kapczynski, A Mscisz, J Lutomski, H O Meissner, W Kapczynski, A Mscisz, J Lutomski

Abstract

Objective: This double-blind, placebo-corrected clinical pilot study was aimed at assessing the use of hypocotyls of cruciferous Andean plant Maca (Lepidium peruvianum Chacon), in alleviating symptoms of menopausal discomfort experienced by women in early post menopause as measured by profiles of serum hormones: Luteinizing Hormone (LH), Follicle-stimulating Hormone (FSH), Estrogen (E2) and Progesterone (PG) and as assessed by Greene's Menopausal Index.

Design: Study was conducted on 20 Caucasian healthy early-postmenopausal women volunteers during the three months period (Trial I) and on eight women during nine months period (Trial II). Hormone levels were determined in blood with a simultaneous assessment of menopausal index at the start of study, after one month use of placebo, and after two and eight months administration of 2g gelatinized Maca root powder (Maca-GO) in the form of two 500mg hard gel capsules, twice daily.

Results: In comparison to placebo, after both, two and eight months administration of Maca-GO capsules to EPMW, level of FSH significantly (P<0.05) decreased with a simultaneous significant (P<0.05) increase in the LH level, resulting in significant (P<0.05) increase in both E2 and PG, after eight months of Maca-GO treatment only. There was a significant (P<0.05) placebo effect resulting in an elevated PG level after one month administration of placebo capsules. Changes in hormone levels was accompanied by substantially-reduced feeling of discomfort associated with menopause, although, there was a distinctive, positive placebo effect as judged by responses to Greene's questionnaire.

Conclusions: It is reasonable to suggest that Maca-GO when used in EPMW, depending on the length of use, was acting as a toner of hormonal processes as reflected by decrease in FSH and increased LH secretion, which stimulated production of both ovarian hormones, E2 and PG and resulted in a substantial reduction of menopausal discomfort felt by women participating in the study, with a distinctive placebo effect, thus, fully justifying further, more complex study on effectiveness of Maca-GO as a reliable alternative to HRT program.

Keywords: hormones; maca (lepidium peruvianum); plant alternative to HRT; post menopause.

References

    1. Lutomski J. Maca-energizing food or medicine? Postepy Fitoterapii. 2001;6:15.
    1. Chacon RG. Peru: Univ. Natl. Mayo de San Marcos; 1961. Phytochemical study on Lepidium meyenii. PhD Thesis; pp. 1–46.
    1. Zurowska K. Gdansk: Tower Press; 2001. Herbal Therapies from Amazon and Andes-Maca (In Polish: Ziololecznictwo Amazonskie i Andyjskie-Maca) pp. 1–101.
    1. Walker M. Effect of Peruvian Maca on Hormonal Functions. Townsend Letter for Doctors and Patients. 1998;11:18.
    1. Muller V. Maca in Hormone Replacement Therapy. Whole World Botanicals Report. 1997. pp. 1–7.
    1. Muller V. South American Herb Maca as Alternative to Hormone Replacement Therapy. Whole World Botanicals Report. 2002. p. 11.
    1. Gonzales GF, Cordova A, Gonzales C, et al. Lepidium meyenii (Maca) improved semen parameters in adult men. Asian J. Androl. 2001;3(4):301.
    1. Gonzales GF, Ruiz A, Gonzales C, et al. Effect of Lepidium meyenii (Maca) roots, a Peruvian plant on spermatogenesis of male rats. Asian J. Androl. 2001;3:231.
    1. Zheng BL, He K, Kim CH, et al. Effect of lipidic extract from Lepidium meyenii on sexual behaviour in mice and rats. Urology. 2000;55:598.
    1. Obregon LV. 1st. Lima: Instituto de Fitoterapia Americano; 2001. “Maca” Planta Medicinal y Nutritiva del Peru; pp. 1–182.
    1. Malaspina H. New York: Whole World Botanicals; 1997. Therapeutic use of Maca (Lepidium peruvianum C.) in medical practice. Interview by V. Muller; pp. 1–5.
    1. Ostrowski-Meissner H, Kapczyński W, Mścisz A, et al. An Attempt to Use Maca (Lepidium peruvianum) in Post Menopausal Women. Advances in Phytotherapy. 2003;4:19.
    1. Chacon G. 1st. Lima: Universidad Nacional Mayor de San Marcos; 2001. “Maca” Millenarian Peruvian Food Plant with Highly Nutritional and Medicinal Properties; pp. 1–337.
    1. Brako L, Zarucchi JL. St Louis: Missouri Botanical Garden; 1993. Catalogue of the Flowering Plants and Gymnosperms of Peru; p. 229.
    1. Greene J. Constructing a standard climacteric scale. Maturitas. 1998;9:76.
    1. Liske E, Wustenberg P. Therapy of climacteric complaints with Cimicifuga racemosa: herbal medicine with clinically proven evidence. Menopause. 1998;5:250.
    1. Shaper S, Brummer T. Remifemin-Active Substance: Liquid Cimicifuga Extract. The Herbal Preparation for Gynecology. 1997:43.
    1. Clifton-leight P, Barber R, Fulcher G, et al. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause. 2001;8(4):259.
    1. Husband AJ. Red Clover isoflavone supplement: Safety and pharmokinetics. Journal of the British Menopause Society. 2001;(Supplement S1):4.
    1. Nightigalle LE. Isoflavones in management of menopause. Journal of the British Menopause Society. 2001;(Supplement S1):8.
    1. Lopez-Fando A, Gomez-Serranillos MP, Iglesias I, et al. Lepidium peruvianum Chacón restores homeostasis impaired by restraint stress. Phytother. Res. 2004;18(6):471.
    1. Dini A, Migliuolo G, Rastrelli L, et al. Chemical composition of Lepidium meyenii. Food Chemistry. 1994;49:347.
    1. Genyi Li, Ammermann U, Quiros CF. Glucosinolate contents in Maca (Lepidium Peruvianum Chacon) seeds, sprouts, mature plants and several derived commercial products. Economic Botany. 2001;55(2):255.
    1. Wattenberg LW. Inhibition of carcinogen-induced neoplasia by sodium cyanate, tert-butylisocyanate and benzyl isothiocyanate administered subsequent to carcinogen exposure. Cancer Research. 1981;41:2991.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere